Christopher R. Nicholas

TL;DR: A randomized, double-blind, randomized, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) was conducted to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma as discussed by the authors.

TL;DR: Lejuez et al. as discussed by the authors conducted a randomized controlled trial comparing individualized BATD and a no-treatment control for university students with moderate depression, environmental reward, social support, andsomatic anxiety.

TL;DR: The small amount of psilocin renally excreted suggests that no dose reduction is needed for subjects with mild–moderate renal impairment, and simulation of fixed doses using the pharmacokinetic parameters suggest that an oral dose of 25 mg should approximate the drug exposure of a 0.3 mg/kg oral doseof psilocybin.

TL;DR: Results tentatively support future research on psilocybin for the treatment of anxiety and depression in samples with elevated symptoms.

TL;DR: The results suggest that social defeat activates neurons in select subregions of the DRN and reduces message for DRN 5-HT1A autoreceptor-mediated inhibition, and lead to hyperactivity of 5- HT neurons.